Physician profile
Imran Ahmed
NPI 1679650949
$3,462.28
in general payments reported to CMS, 2019-2025
43 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $66.90 · 2021: $252 · 2022: $83.58 · 2023: $981 · 2024: $1,044 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742 · Education: $34.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.64 |
| Education | $34.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $506.11 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $392.05 | 2023-2025 | |
| Exelixis INC. | $217.18 | 2019-2024 | Cabometyx |
| Seagen INC. | $196.84 | 2021-2023 | Adcetris |
| Amgen INC. | $166.13 | 2022-2023 | Nplate, Lumakras, Vectibix |
| E.R. Squibb & Sons, L.L.C. | $155.34 | 2020-2025 | Opdivo, Eliquis, Opdualag |
| Astellas Pharma US INC | $152.47 | 2023-2024 | Xtandi, Padcev, Xospata |
| Boston Scientific Corporation | $150.19 | 2023 | Icefx Cryoablation System |
| Neurocrine Biosciences, INC. | $103.69 | 2019 | |
| Glaxosmithkline, LLC. | $100.16 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $88.56 | 2021-2024 | Trodelvy |
| Array Biopharma INC | $82.30 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Intuitive Surgical, INC. | $82.04 | 2024 | |
| Janssen Biotech, INC. | $79.72 | 2023-2025 | Imbruvica, Rybrevant, Erleada |
| Tempus Ai, INC | $77.68 | 2024-2025 | Xt Cdx |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $72.90 | 2023-2025 | Bavencio |
| Pfizer INC. | $70.40 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $62.64 | 2021-2024 | Keytruda |
| Genzyme Corporation | $53.67 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.46 | 2020-2023 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $50.34 | 2023-2024 | Libtayo |
| Genmab U.S., INC. | $49.89 | 2023-2024 | Epkinly |
| Mirati Therapeutics, INC. | $49.70 | 2023-2024 | Krazati |
| Astrazeneca Pharmaceuticals LP | $39.39 | 2024-2025 | Imfinzi |
| Servier Pharmaceuticals LLC | $39.13 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.76 | 2024 | Fruzaqla |
| Sobi, INC | $29.78 | 2024 | |
| Sumitomo Pharma America, INC. | $27.58 | 2024 | Orgovyx |
| Beigene USA, INC. | $24.50 | 2023 | Brukinsa |
| Tactile Systems Technology INC | $24.44 | 2024 | Entre Plus, Flexitouch Plus |
| Sun Pharmaceutical Industries INC. | $24.20 | 2023 | Odomzo, Yonsa |
| Octapharma USA, INC. | $21.63 | 2021 | |
| Eisai INC. | $20.21 | 2023 | |
| Genentech USA, INC. | $19.85 | 2023 | Lunsumio, Gavreto, Alecensa |
| Rigel Pharmaceuticals, INC. | $19.73 | 2023 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $19.67 | 2023 | Imbruvica |
| Kyowa Kirin, INC. | $19.07 | 2023 | Poteligeo |
| Bayer Healthcare Pharmaceuticals INC. | $18.34 | 2023 | |
| Caris Mpi, INC. | $14.94 | 2025 | Mi Cancer Seek |
| Galvanize Therapeutics, INC | $14.66 | 2024 | Aliya System |
| Abbvie INC. | $14.61 | 2025 | |
| Alexion Pharmaceuticals, INC. | $14.29 | 2024 | Ultomiris |
| Puma Biotechnology, INC. | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.